CCN5 activation by free or encapsulated EGCG is required to render triple‐negative breast cancer cell viability and tumor progression

• Main Authors: Amlan Das, Inamul Haque, Priyanka Ray, Arnab Ghosh, Debasmita Dutta, Mohiuddin Quadir, Archana De, Sumedha Gunewardena, Indranil Chatterjee, Snigdha Banerjee, Scott Weir, Sushanta K. Banerjee
• Format: Article
• Language: English
• Published: Wiley 2021-04-01
• Series: Pharmacology Research & Perspectives
• Subjects: bioavailability; breast cancer; CCN5; drug delivery; EGCG; FA‐PEG‐NPs
• Online Access: https://doi.org/10.1002/prp2.753

Abstract Epigallocatechin‐3‐gallate (EGCG) has been considered an anticancer agent despite conflicting and discrepant bioavailability views. EGCG impairs the viability and self‐renewal capacity of triple‐negative breast cancer (TNBC) cells and makes them sensitive to estrogen via activating ER‐α. Surprisingly, the mechanism of EGCG’s action on TNBC cells remains unclear. CCN5/WISP‐2 is a gatekeeper gene that regulates viability, ER‐α, and stemness in TNBC and other types of cancers. This study aimed to investigate whether EGCG (free or encapsulated in nanoparticles) interacts with the CCN5 protein by emphasizing its bioavailability and enhancing its anticancer effect. We demonstrate that EGCG activates CCN5 to inhibit in vitro cell viability through apoptosis, the sphere‐forming ability via reversing TNBC cells’ stemness, and suppressing tumor growth in vivo. Moreover, we found EGCG‐loaded nanoparticles to be functionally more active and superior in their tumor‐suppressing ability than free‐EGCG. Together, these studies identify EGCG (free or encapsulated) as a novel activator of CCN5 in TNBC cells and hold promise as a future therapeutic option for TNBC with upregulated CCN5 expression.